GMRx2 Placebo Controlled Trial (PCT)
The GMRx2-ICTU team is proud to setup 10 primary care sites in the UK to for the GMRx2-Placebo Controlled Trial (PCT) study.
This phase III trial will investigate George Medicines proprietary triple low-dose combination GMRx2 pill for the treatment of hypertension compared to placebo.
This international multi-centered study (US, Australia, Sri Lanka and Nigeria) hopes to recruit over 300 patients globally with approximately 100 patients from the UK.
The GMRx2-ICTU team have also been tasked to set up three sites in Nigeria for the PCT study in the coming weeks.